AbCellera Biologics Inc.

NASDAQ•ABCL

CEO: Dr. Carl L.G. Hansen Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2020-12-11

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Contact Information

2215 Yukon Street, Vancouver, BC, V5Y 0A1, Canada

604-559-9005

www.abcellera.com

Market Cap

$1.08B

P/E (TTM)

-7.3

17.5

Dividend Yield

52W High

$6.52

52W Low

$1.89

52W Range

36%

Rank37Top 34.1%

4.4

F-Score

Modified Piotroski Analysis

Based on 7-year fundamentals

Average • 4.4 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2019-2025

Financial Dashboard

Q4 2025 Data

Revenue

$44.85M+0.00%

4-Quarter Trend

EPS

-$0.03+0.00%

4-Quarter Trend

FCF

-$44.59M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Significant Revenue Increase Total revenue reached $75.1M USD in 2025, marking a 161% increase from $28.8M USD in 2024.

Loss from Operations Reduced Loss from operations narrowed to ($217.1M) USD in 2025, improving from ($314.8M) USD last year.

Internal Pipeline Progressing Advanced two internal drug candidates into clinical trials; 19 total molecules now in the clinic.

Manufacturing Facility Operational Completed clinical manufacturing facility investment, shifting focus to pipeline development and value realization.

Risk Factors

Incurred Losses Continue Incurred losses in 2025 ($146.4M USD net loss); profitability timing remains uncertain, requiring continued expenditures.

Drug Development Inherent Risk Drug candidates face inherent uncertainty; none may achieve marketing approval or become viable commercial drugs.

Reliance on Partner Success Future value heavily depends on partners successfully developing and commercializing discovered antibodies for royalties.

Cash Reserves Decreasing Total cash, equivalents, and securities decreased 14.7% to $533.8M USD by year-end 2025.

Outlook

Internal Pipeline Investment Allocating substantial resources to internal pipeline development, expecting near-term losses before long-term revenue.

Key Data Readouts Expected Anticipate topline data for ABCL635 in Q3 2026 and ABCL575 in Q4 2026 from ongoing trials.

Leveraging Integrated Platform Utilizing completed integrated platform investments to drive first-in-class medicines against challenging targets.

Anticipated IND/CTA Submissions Plan to submit IND/CTA for next two internal programs, ABCL688 and ABCL386, during 2027.

Peer Comparison

Revenue (TTM)

XERS

$291.85M

+43.7%

RCUS

$247.00M

-4.3%

SYRE

$90.49M

+0.0%

Gross Margin (Latest Quarter)

CLDX

100.0%

+0.0pp

ABCL

100.0%

+588.5pp

NUVB

99.0%

+182.9pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
CELC	$5.42B	-32.2	-179.0%	67.3%
EWTX	$3.14B	-18.0	-32.0%	0.7%
VERA	$2.87B	-8.6	-59.7%	10.5%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

119.6%

Strong Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 6, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data